Kardigan

Executive Summary

Kardigan is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts, founded in 2021 with a mission to make cardiovascular disease preventable and curable. The company leverages a proprietary platform integrating artificial intelligence and real-world data to accelerate drug discovery and development, focusing on targeted small molecules that address root causes rather than symptoms. Currently in Phase 2, Kardigan aims to transform cardiovascular care by developing medicines with the potential to halt or reverse disease progression. Its AI-driven approach enables efficient identification and validation of novel targets, reducing typical development timelines and costs. With a strong emphasis on precision medicine, Kardigan is positioned to address significant unmet needs in cardiovascular disease, a leading cause of morbidity and mortality worldwide. The company's strategy combines cutting-edge technology with deep biological insights to advance a pipeline of first-in-class and best-in-class therapies, targeting pathways implicated in atherosclerosis, heart failure, and other cardiometabolic conditions. As a private entity, Kardigan is poised for significant milestones that could de-risk its pipeline and attract strategic partnerships or financing.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 top-line data readout for lead asset60% success
• Q4 2026Series B or C financing round80% success
• Q1 2027Research collaboration or licensing deal with a major pharma50% success